ARE Stock Analysis — Alexandria Real Estate Equities
Sector: REITs
AI Verdict
At 47.0x next year’s earnings and with revenue shrinking -9.5% YoY, you’re paying a premium the numbers don’t yet support, even if the specialized lab moat is real.
Competitive Moat
Alexandria specializes in life sciences campuses clustered in top biotech hubs, offering lab space that is difficult and expensive for competitors to replicate. Their long-term tenant relationships with major pharma and biotech firms create high switching costs and stable occupancy.
Summary
ARE stands out for its focus on purpose-built lab campuses in prime biotech locations, a niche with high barriers to entry.
Where It Stands
Shares are down -37.67% over the past year, with a cooling RSI of 39.7 and a steep 47.0x forward P/E versus the REIT sector’s typical low double digits.
Key Metrics
- RSI: 39.7 — Near Oversold
- Forward P/E: 47.0x
- Revenue Growth: -0.1%
- Market Cap: $8.4B
- Dividend Yield: 0.06%
- 1-Year Return: -37.67%
- 52-Week High: $88.24
- 52-Week Low: $39.41
Analyst Consensus
3 Buy · 14 Hold · 8 Sell (25 analysts)
Bull Case
The 47.0x forward P/E reflects the scarcity value of specialized life sciences real estate, which could support a rebound if sector demand stabilizes.
Bear Case
If the 47.0x forward P/E compresses even halfway toward the REIT sector median, the stock could see another large leg down from current levels.
Catalyst to Watch
Watch for new long-term lease signings or occupancy updates—if tenant demand weakens further, the premium multiple is at risk.